Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126595) titled 'A Clinical Study on the Efficacy and Safety of Continuous Ixazomib and Pomalidomide Therapy after BCMA CAR-T Treatment in High-Risk Multiple Myeloma' on June 11.

Study Type: Observational study

Study Design: Cross-sectional

Primary Sponsor: Beijing Chao-Yang Hospital, Capital Medical University

Condition: high-risk multiple myeloma

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-07-15

Target Sample Size: Observation Group:62;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=324754

Published by HT Digital Content Services wi...